Research Topic: clinical pharmacology

Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Subjects

mycolabadmin

This study examined whether taking the antidepressant escitalopram before using psilocybin affects the drug’s effects. Twenty-three healthy participants took either escitalopram or placebo for two weeks, then received a dose of psilocybin. Surprisingly, escitalopram did not reduce the positive mood effects of psilocybin and actually reduced some negative side effects like anxiety and bad feelings. The combination appeared safe with no increased cardiovascular risks.

Read More »

Ketanserin Reverses the Acute Response to LSD in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Participants

mycolabadmin

Researchers tested whether ketanserin, a drug that blocks serotonin receptors, could stop or reverse an LSD experience once it had already started. In a controlled study with healthy volunteers, ketanserin given one hour after LSD administration cut the duration of the LSD experience from 8.5 hours down to 3.5 hours and eliminated visual and auditory hallucinations. This finding suggests ketanserin could be useful as an emergency medication in psychedelic-assisted therapy to help patients who have negative reactions to LSD.

Read More »

Psilocybin as Transformative Fast-Acting Antidepressant: Pharmacological Properties and Molecular Mechanisms

mycolabadmin

Psilocybin, a compound from certain mushrooms, is being studied as a potential rapid-acting treatment for severe depression that doesn’t respond to standard antidepressants. Unlike conventional antidepressants that take weeks to work, psilocybin shows promise for producing mood improvements within days. The drug works by activating serotonin receptors in the brain and promoting the growth of new neural connections, though researchers are still working to fully understand how it achieves its antidepressant effects.

Read More »

Randomized control trial to study the effectiveness of tablet Fluconazole, capsule Itraconazole and tablet Terbinafine in superficial dermatophytosis

mycolabadmin

This study tested three common antifungal medications used to treat fungal skin infections like ringworm. The research involved 180 patients who were randomly given one of three drugs and then checked at 4 and 8 weeks to see if the infection was gone. Itraconazole worked best, clearing infections in about 87% of patients, followed by Fluconazole at 73%, and Terbinafine at 63%.

Read More »

Enhancing antifungal stewardship: The educational and healthcare benefits of involving pharmacy students in audits

mycolabadmin

Researchers studied how involving pharmacy students in reviewing fluconazole (an antifungal medication) prescriptions could help hospitals improve their antifungal medication use and provide valuable training. Out of 145 prescriptions audited, about two-thirds were appropriate while one-third had issues like unnecessary use or drug interactions. Both the students and hospitals benefited significantly, with students gaining practical clinical experience while hospitals identified prescribing problems that could be improved.

Read More »
Scroll to Top